ALKS 1140 / Alkermes - LARVOL DELTA

Phase 1 ALKS 1140 in Healthy Adults (clinicaltrials.gov) - P1 | N=20 | Terminated | Sponsor: Alkermes, Inc. | N=80 ➔ 20 | Suspended ➔ Terminated; Sponsor Decision

Enrollment change • Trial termination

Phase 1 ALKS 1140 in Healthy Adults (clinicaltrials.gov) - P1 | N=80 | Suspended | Sponsor: Alkermes, Inc. | Recruiting ➔ Suspended

Trial suspension

Phase 1 ALKS 1140 in Healthy Adults (clinicaltrials.gov) - P1; N=80; Recruiting; Sponsor: Alkermes, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Phase 1 ALKS 1140 in Healthy Adults (clinicaltrials.gov) - P1; N=80; Not yet recruiting; Sponsor: Alkermes, Inc.

Clinical • New P1 trial

Alkermes to Hold Virtual Investor Day (Alkermes Press Release) - "Alkermes plc...announced...that it will hold a virtual Investor Day on Thursday, March 25, 2021, beginning at 9:00 a.m. ET (1:00 p.m. GMT). During the event, members of Alkermes' senior management and research and development team will discuss the company's research and development strategy in neuroscience and oncology, review clinical data and strategy related to nemvaleukin alfa (ALKS 4230) and highlight the company's earlier stage development programs, including ALKS 1140."

Clinical • Oncology